News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website


ERC Announces Interim Results from Phase 2 Trial of Immunotherapy ERC1671 (Gliovac) in Recurrent Glioblastoma Patients


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

   This is the early results of a phase 2 randomized clinical trial for recurrent glioblastoma, which shows a remarkable improvement compared to historical controls (they do not discuss how the placebo group in the trial dd).    6 month survival rate was 100% in the trial compared to historical 33%. Median overall survival is 46 weeks compared to historical control of 23 weeks. Presumably some of the patients are still alive and the survivals should increase but they are already at double, and this is with a treatment that usually has minimal side effects.  


Posted on: 08/23/2020

ERC Announces Interim Results from Phase 2 Trial of Immunotherapy ERC1671 in Recurrent Glioblastoma Patients

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740